title: Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion.
abstract: Candesartan cilexetil (CC) is a newer class of angiotensin II receptor antagonist used for the treatment of hypertension. The solubility of the CC is very poor and its oral bioavailability is only 15%. The controlledrelease polar lipid microparticles of CC (formulations F1, F2, F3 and F4) were prepared using variable erodible lipophilic excipients like hydrogenated castor oil, stearic acid, cetostearyl alcohol and carnauba wax by fusion method. The particle sizes of polar lipid microparticles were less than 50 microns and they were irregular in shape. Drug content ranged between 98.96 ± 2.1 and 101.9 ± 1.6% were present in all the formulations. The formulation F3 showed better drug release throughout the study period in a controlled release manner. Moreover, the in vitro release showed that all the formulations were best fitted to Higuchi model. Accelerated stability studies indicated that there was no significant changes in the chemical and physical characteristics of the formulated drug product during initial and at the end of the study period. The FTIR and DSC studies showed that there was no interaction between the drug and lipophilic excipients and no polymorphic transitions in all formulations. The X-ray diffraction peak of solid dispersion indicated that the crystalline nature of CC disappeared and no new peaks could be observed, suggesting the absence of interaction between drug and excipients.
authors.affiliation: Caplin Point Laboratories Limited, Chennai, India ; Department of Pharmaceutical Technology, Anna University of Technology, Tiruchirappalli, India.
authors.forename: V
authors.initials: V
authors.lastname: Kamalakkannan
authors.forename: A
authors.initials: A
authors.lastname: Puratchikody
authors.forename: L
authors.initials: L
authors.lastname: Ramanathan
keywords: Candesartan cilexetil; Diffusion; Higuchi; Korsmeyer-Peppas; Polar lipid microparticles; Solid dispersion
references.citation: Med Clin North Am. 1997 Sep;81(5):1077-97
references.pmid: 9308599
references.citation: Int J Pharm. 2005 Sep 30;302(1-2):103-12
references.pmid: 16102926
references.citation: J Pharm Sci. 1999 Oct;88(10):1058-66
references.pmid: 10514356
references.citation: J Microencapsul. 2009 Aug;26(5):456-69
references.pmid: 19606940
references.citation: Eur J Pharm Sci. 2004 Feb;21(2-3):251-60
references.pmid: 14757497
references.citation: J Clin Hosp Pharm. 1981 Mar;6(1):27-38
references.pmid: 7345094
references.citation: Proc (Bayl Univ Med Cent). 2003 Jan;16(1):123-6
references.pmid: 16278727
references.citation: Expert Opin Pharmacother. 2004 Jul;5(7):1589-97
references.pmid: 15212609
references.citation: Pharm Sci Technol Today. 2000 Jun;3(6):198-204
references.pmid: 10840390
references.citation: J Pharm Sci. 1983 Oct;72(10):1189-91
references.pmid: 6644570
references.citation: J Am Coll Cardiol. 1997 Jun;29(7):1414-21
references.pmid: 9180098
references.citation: Am Fam Physician. 1999 Jun;59(11):3140-8
references.pmid: 10392595
references.citation: J Pharm Sci. 1961 Oct;50:874-5
references.pmid: 13907269
references.citation: J Pharm Sci. 1963 Dec;52:1145-9
references.pmid: 14088963
references.citation: Pak J Pharm Sci. 2009 Apr;22(2):234-46
references.pmid: 19339238